Author:
Xiao Jing,Xiang Huanyu,Xiang Hongyan,Sun Zilin,Xu Jing,Ren Hong,Hu Peng,Peng Mingli
Reference50 articles.
1. Microbiomics, metabolomics, predicted metagenomics, and hepatic steatosis in a population-based study of 1,355 adults;Alferink;Hepatology,2021
2. GW9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease;Baumann;Metab., Clin. Exp.,2022
3. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones;Bedoucha;J. Hepatol.,2001
4. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes;Bril;Clin. Gastroenterol. Hepatol.,2018
5. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease;Byrne;Arterioscler. Thromb. Vasc. Biol.,2014
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献